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Ocena składu komórkowego plwociny indukowanej w sarkoidozie
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Abstract
Introduction: The aim of this study was to evaluate the cellular composition of induced sputum (IS) in sarcoidosis and its 
role in assessing the disease activity. The safety of the procedure was also determined.
Material and methods: Sputum induction by inhalation of hypertonic saline was performed. Twenty-one samples from the 
healthy controls, 32 from patients with active disease, and 33 from subjects with inactive disease were analysed.
Results: The percentage of lymphocytes in IS was significantly higher in active sarcoidosis than in inactive disease and the con-
trol group (9.7% vs. 3.1% vs. 2.9%), and was the highest in the patients with parenchymal changes and active disease (13.3%). 
The percentage of macrophages was significantly lower in active sarcoidosis than in normal subjects (76.8% vs. 83.4%). It was 
also significantly lower in IS in active disease and stages II and III than in both subgroups with active and inactive stage I of sar-
coidosis. There were no significant differences in the IS cell percentages between the whole sarcoidosis group and the controls. 
Sputum induction was well tolerated and stopped only four times, two of them because of dyspnoea or the decrease of PEF. 
The symptoms were well reversible after administering salbutamol.
Conclusions: Sputum induction by inhalation of hypertonic saline is safe, but the evaluation of IS differential cell counts is 
not useful in sarcoidosis diagnosing. However, it could be used in assessing the activity of the disease, especially in patients 
with interstitial lung changes.
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Streszczenie
Wstęp: Celem pracy była analiza składu komórkowego plwociny indukowanej (PI) u chorych na sarkoidozę i ocena, czy 
różnice we wzorze odsetkowym komórek pozwalają określić aktywność choroby. Oceniano także bezpieczeństwo procedury. 
Materiał i metody: Indukcję plwociny przeprowadzano przez inhalację hipertonicznego roztworu chlorku sodu. Do analiz 
włączono 21 materiałów uzyskanych od osób zdrowych, 32 od chorych z aktywną i 33 od osób z nieaktywną sarkoidozą. 
Wyniki: Odsetek limfocytów był istotnie wyższy w PI w aktywnej sarkoidozie niż w chorobie nieaktywnej i u osób zdrowych 
(9,7 v. 3,1 i 2,9%). Najwyższy był on w materiale od chorych z aktywną chorobą i zmianami miąższowymi w płucach (13,3%). 
Odsetek makrofagów był istotnie niższy w aktywnej chorobie niż u osób zdrowych (76,8 v. 83,4%). W PI od osób z aktywną 
chorobą w fazach II i III był on także niższy, niż w fazie I sarkoidozy, niezależnie od aktywności choroby. Nie było natomiast 
różnicy we wzorze odsetkowym komórek w PI pomiędzy całą grupą chorych na sarkoidozę a grupą kontrolną.
We wszystkich badanych grupach procedura indukcji plwociny była dobrze tolerowana, przerwano ją tylko 4 razy, w tym 
dwukrotnie z powodu duszności lub spadku PEF. Objawy te szybko ustąpiły po podaniu dodatkowej dawki salbutamolu.
Wnioski: Indukcja plwociny przez inhalację hipertonicznego roztworu chlorku sodu jest procedurą bezpieczną, ocena jej skła-
du komórkowego nie przydaje się jednak w diagnostyce sarkoidozy. Może ona natomiast służyć ocenie aktywności choroby, 
zwłaszcza u osób ze zmianami w miąższu płuc.
Słowa kluczowe: sarkoidoza, plwocina indukowana, bezpieczeństwo
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Persons included in the study were non- 
-smokers and had no symptoms of respiratory tract 
infection during the four weeks preceding the trial. 
All participants gave written informed consent, 
the formulary of which had been approved by the 
Independent Bioethical Committee of the MUG.
Anamnesis was taken, and physical exami-
nation was performed in all subjects, followed by 
spirometry (spirometer Pneumo-Record, abcMed, 
Poland). The results of the spirometry testing were 
interpreted according to the generally accepted 
criteria [18]. Chest X-ray was taken in patients with 
sarcoidosis and then used for assessment of disease 
stage [9, 19]. All patients in the control group had 
normal chest X-rays, taken as part of periodic he-
alth assessment at their workplace or school within 
12 months preceding the current study.
Other investigations were performed in pa-
tients with sarcoidosis when needed, as part of 
routine diagnostic work-up and depending on 
particular indications. These included bronchofi-
beroscopy with BAL (in 37 patients), high resolu-
tion computed tomography (HRCT) scanning of the 
chest (in 56 patients), and microscopic evaluation 
of tissue or cytological samples. Diagnosis of sar-
coidosis was made according to recommendations 
of the international expert panel of the American 
Thoracic Society/European Respiratory Society/ 
/World Association of Sarcoidosis and other Gra-
nulomatous Diseases (ATS/ERS/WASOG) [9].
Sarcoidosis was classified as active (group A) 
in patients having signs of Löfgren syndrome or 
presenting two or more of the following signs: 
lymphocytosis in BAL fluid exceeding upper 
normal limit, i.e. 15% [20], CD4+/CD8+ ratio 
in BAL fluid > 3.5; ground-glass attenuation on 
chest HRCT scans as well as clinical symptoms 
(cough, dyspnoea, chest discomfort) observed for 
the first time or progressing during the previous 
three months; worsening of spirometry results; or 
disease progression confirmed radiologically in 
chest scans [9, 21]. In all other cases, sarcoidosis 
was classified as non-active (group B).
Sputum induction was performed 15 minu-
tes after inhalation of 200 μg salbutamol, during 
four cycles of 5 minutes each, according to the 
previously described protocol [22, 23], modified 
through the usage of 5% saline solution (NaCl). 
An ultrasound nebuliser Thomex MB (MEDBRYT, 
Warsaw, Poland) was used for aerosol production. 
Each participant rinsed his or her mouth with 
water after each inhalation cycle, and, if coughing 
began, spat out the entire expectorate into a conta-
iner. Before and after each inhalation cycle three 
measurements of peak expiratory flow (PEF) were 
Introduction
Inhalation of hypertonic saline (NaCl) aerosol 
as a safe method of provoking sputum production 
and expectoration was first described in 1958 by 
H. Bickerman, who applied it in patients with lung 
cancer in order to obtain material from the lower 
respiratory tract for cytological analysis [1]. The 
method was also used for diagnostics of pulmo-
nary tuberculosis and pneumocystodosis [2, 3]. 
In 1992, Isabelle Pin suggested using the induced 
sputum technique (IS) for the assessment of airway 
inflammation in patients with asthma [4]. Since 
then, the method has been developing and is now 
widely applied in other diseases of the respiratory 
tract [5–8].
Sarcoidosis is a multisystem granulomatous 
disease of young and middle-aged adults, which 
predominantly affects the lungs and intra-thoracic 
lymph nodes [9]. The granuloma formation in lung 
parenchyma is preceded by the accumulation of in-
flammatory cells with macrophages and lymphocytes 
predominance [10, 11]. The type of cells engaged in 
lower respiratory tract inflammation could be asses-
sed by bronchoalveolar lavage (BAL) fluid analysis, 
which is a commonly used diagnostic method in 
sarcoidosis [9, 12]. It has been demonstrated that 
cellular pattern of BAL fluid reflects the cellular 
composition of inflammatory infiltrates in lung pa-
renchyma [13, 14]. Non-invasive sputum induction 
method was recently suggested for this purpose 
[5, 15–17]. The potential role of this investigation in 
interstitial lung diseases has not yet been established.
The aim of the study was to analyse the cell 
composition of IS from patients with sarcoidosis 
affecting thoracic organs as well as to assess if va-
rying cell differential counts can reflect the activity 
of the disease.
The safety of the procedure was also assessed 
in the studied population.
Material and methods
The study group included 87 patients with 
sarcoidosis affecting thoracic organs, who were not 
treated with glucocorticosteroids or immunosup-
pressants within at least three months preceding 
induction. The study subjects were recruited from 
patients of the Pneumonology Department of the 
Medical University of Gdańsk (MUG) and of the 
outpatient clinic for lung diseases.
The control group included 32 healthy per-
sons, comprising medical students and friends 
and personnel of the Pneumonology Department 
of MUG.
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performed and the maximal obtained reading was 
recorded. In cases of PEF decrease ≥ 20% from 
baseline value, the procedure was interrupted, an 
additional dose of salbutamol was administered, 
and PEF was controlled again. In several subjects 
who did not produce IS during the first attempt 
but agreed to have another one, induction was 
performed again after one week.
Induction procedures were carried out early 
in the day, following BAL, not earlier than three 
days (average 5.9 days) after bronchofiberoscopy.
The volume of expectorate was measured, and 
samples smaller than 1 ml were excluded from 
the study [24]. Samples of adequate volume were 
examined within 2 hours. The whole expectorate 
of sputum plus saliva was processed according to 
procedures described by other authors and to re-
commendations of the ERS working group [25–27].
In order to homogenise the obtained samples, 
0.1% dithiothreitol (DTT) solution was added in 
the same amount as the expectorate and then put 
in a shaking water bath at 37°C for 15 minutes. 
Subsequently, phosphate buffer saline solution 
(PBS) was added at an equal amount to the sample 
containing IS and DTT.
Total cell count per μl of the processed sample 
was then assessed by flow cytometry (Cell Dyn 
3200, Abbott, USA), and two cytospin slides were 
prepared using 300 ml of the solution for each of 
them (Cytospin 3, Shandon Southern Instruments, 
USA). These were stained with May-Grünwald- 
-Giemsa and analysed by an experienced cytologist, 
who received no information about the patients. 
Differential cell count was performed incorporating 
all the cells contained in the cytospin preparations, 
including at least 400 non-squamous cells. Diffe-
rential count of macrophages (M), eosinophils (E), 
lymphocytes (L), neutrophils (S), and bronchial 
epithelial cells (N), excluding squamous epithelial 
cells, was then reported [28, 29]. The percentage of 
squamous epithelial cells was reported separately 
as a marker of sample contamination by cells from 
the oral cavity (saliva). Only adequate samples 
were included in the final analysis, these being 
of more than 1 ml in volume [24] and containing 
<80% squamous epithelial cells [29–31]. Total cell 
count (cytosis) was calculated for each obtained 
induced sputum sample, including the total amo-
unt of inflammatory cells in the sample (M, E, L, 
S and N), and excluding squamous epithelial cells 
originating from the nasopharynx.
Sputum induction was performed 94 times in 
87 patients with diagnosed or suspected sarcoido-
sis. These procedures yielded adequate material in 
68 cases, of which three were excluded because 
diagnosis of sarcoidosis was not confirmed in these 
subjects. Among the remaining 65 persons, active 
disease was diagnosed in 32 subjects (group A) and 
non-active sarcoidosis in 33 patients (group B).
Group A included 32 patients with sarcoidosis 
diagnosed for the first time ever (20 subjects) or 
presenting relapse or recurrence of the previously 
diagnosed disease (12 persons). Diagnosis was confir-
med histopathologically in 24 patients (75%). Group 
A included 15 patients with stage I, 13 subjects with 
stage II, and four persons with stage III disease. 
Group B consisted of 33 patients, of whom 
18 had stable disease, 12 had radiological signs 
of regression, and three were currently diagnosed 
with sarcoidosis (for the first time ever) but had 
non-active disease. Histopathological confirma-
tion was obtained in 28 cases (84.8%). The group 
included 12 patients with stage I, 10 with stage II, 
and 10 with stage III disease. In one patient the 
disease stage was classified as II/IV.
Sputum induction was performed 35 times in 
32 persons in the control group, obtaining diagno-
stically adequate samples in 22 cases. Of those, one 
sample was excluded from final analysis as being 
clearly aberrant; this was a sample from a woman 
in her thirties, working in microbiology laborato-
ry, which disclosed a high level of lymphocytosis 
(13%). The remaining samples from 21 patients 
were included in the analysis, and are referred to 
as group K (control group).
Patient characteristics are presented in Table 1.
Statistical analysis
Normal distribution of the obtained differen-
tial counts in IS was verified using Shapiro-Wilk 
test. Differences in percentages of respective cell 
types and in total cell count between the groups 
were analysed using Mann-Whitney U test. Stati-
stical significance of changes in PEF value during 
induction was assessed using Wilcoxon test for 
matched pairs. The level of statistical significance 
was adopted for p < 0.05.
Results
The volume of the obtained expectorate did 
not differ significantly between the groups. The 
respective mean volumes were: 3.8 ml in group A 
(range 2–12.5), 4.2 ml in group B (2–9.8), and 4.2 ml 
in group K (1.6–9.8). The percentage of squamous 
epithelial cells was significantly lower in samples 
from healthy subjects as compared to patients with 
sarcoidosis, with mean values of 39.1% in group A 
(range 4–79; p = 0.042), 39.9% in group B (2–79; 
p = 0.027), and 26.6% in group K (2–79).
Maria Porzezińska et al., Induced sputum in sarcoidosis
195www.pneumonologia.viamedica.pl
The distribution of total cell count per sample 
ml and distribution of lymphocyte percentage in 
IS were normal in group K, the others were incon-
sistent with normal distribution.
Patients with active sarcoidosis (group A) had 
significantly higher lymphocyte percentage in IS 
as compared to groups B and K. These patients 
also had significantly fewer macrophages than 
persons in group K. There were no differences in 
differential cell counts in IS between patients with 
non-active sarcoidosis and healthy subjects. The 
percentage of bronchial epithelial cells in group A 
was higher than it was in group K, with a nearly 
significant difference (p = 0.05). Detailed results 
are presented in Table 2.
For the purpose of further analysis, patients 
with sarcoidosis were assigned to subgroups of 
different disease stage. Two subgroups were thus 
identified in the group of patients with active 
disease as well as in the group with non-active 
sarcoidosis. The respective subgroups consisted of 
cases with parenchymal lung changes (combined 
stage II and III disease), and subjects with stage I 
disease. The highest lymphocyte percentages were 
found in IS from patients with active stage II and 
III sarcoidosis, and were significantly higher as 
compared to samples from patients with non-active 
disease, both stage I (p = 0.048), combined stage II 
and III (p = 0.0048), and compared to the control 
group (p = 0.006). Lymphocyte percentages were 
also higher compared to samples from patients 
with stage I active disease, but the difference was 
non-significant (p = 0.22). 
The percentage of macrophage in IS in stage 
II and III active sarcoidosis was significantly 
lower compared to stage I active disease (p = 
0.024), stage I non-active disease (p = 0.0016), 
and to the control group (p = 0.007). In patients 
with stage II and III non-active sarcoidosis, ma-
crophage percentages in IS were significantly 
lower than in stage I non-active disease (p = 
0.018). Differential cell counts in IS from patients 
in the respective subgroups and control group 
are presented in Table 3.
Analysis of all patients with sarcoidosis (gro-
ups A and B combined) showed no significant dif-
ferences in differential cell count in IS as compared 
to the control group. There was a trend for higher 
lymphocyte percentage in patients with sarcoidosis 
as compared to the control group (6.3% vs. 2.9%) 
but the difference was not statistically significant 
(p = 0.26). Detailed results are presented in Table 2.
The procedure of sputum induction was well 
tolerated by the healthy subjects and the patients 
with sarcoidosis. Peak expiratory flow (PEF) valu-
es were measured before and after each induction 
cycle, for safety reasons. A small but statistically 
significant decrease in PEF value from baseline 
was observed after each induction cycle. In the 
entire analysed population, mean PEF decrease 
from baseline was 18.68 l/min (4.1%) after the first 
cycle, 16.25 l/min (3.5%) after second, 20.43 l/ 
/min (4.4%) after the third, and 20.31 l/min (4.4%) 
after the fourth induction cycle. Figure 1 demon-
strates the decrease in PEF value during sputum 
induction in patients with sarcoidosis and in the 
control group. 
Sputum induction was interrupted four ti-
mes during all 129 procedures. A female patient 
in her fifties, with stage I sarcoidosis and normal 
baseline spirometry, experienced a PEF decrease 
of 33.9% (from 530 l/min to 350 l/min) after the 
first induction cycle but reported no dyspnoea. 
An additional dose of salbutamol was administe-
red, and 30 minutes later PEF increased again to 
500 l/min. A week later sputum induction was per-
formed again in the patient, and maximal observed 
PEF decrease was of 9.8% from baseline, measured 
Table 1. The characteristics of examined groups — a number of cases with each abnormality
The  
number of 
cases
The mean 
age  
(range)
FEV1 
% 
pred.
VC % 
pred.
Abnormal 
spirome-
tric test
Symp-
toms 
from re-
spiratory 
tract
Löfgren 
syndrome
Lympho-
cytosis in 
BAL  
> 15 %
CD4/CD8 
in BAL
> 3,5
„Groung 
glass 
opacity” 
in HRCT
Group A 32
(14K,18M)
39.1
(24–68)
84.44 85.14 17 21 13 6 20 9
Group B 33
(15K,18M)
42.6 *
(23–64)
89.79 90.22 12 7 0 0 1 0
Group K 21
(11K,10M)
35.2
(23–69)
104.15 104.11 0 0 0 – – –
* the difference is statistically significant versus group K (p < 0.05)
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Table 2.  The absolute cell counts and differential cell counts of IS in examined groups. The values are mean ± SD
% Group A+B
(n = 65)
Group A
(n = 32)
Group B
(n = 33)
Group K
(n = 21)
Macrophages 80.1 ± 16.4 76.8 ± 19.1 83.2 ± 12.7 83.4 ± 18.5*
Lymphocytes 6.3 ± 9.1 9.7 ± 11.6 3.1 ± 3.6* 2.9 ± 2.2*
Eosinophiles 0.6 ± 1.9 0.9 ± 2.4 0.3 ± 1.3 0.7 ± 1.5
Neutrophiles 10.6 ± 11.8 10.0 ± 11.6 11.1 ± 12.1 11.7 ± 18.4
Bronchial epithelial cells 2.4 ± 3.3 2.5 ± 2.9 2.3 ± 3.7 1.3 ± 1.6
Absolute cell count 0.997 ± 1.061# 1.174 ± 1.166 0.825 ± 0.933* 1.445 ± 1.005
The absolute cell count presents a numer of cells x 103/μl material 
*the difference is statistically significant versus group A (p < 0.05) 
#the difference is statistically significant versus group K (p < 0.05)
Table 3.  The differential cell counts of IS according to stage and activity of the disease. The values are mean ± SD
% Stage I A Stage II/III A Stage I B Stage II/III B Group K
Macrophages 85.3 ± 9.0* 69.3 ± 22.6# 89.9 ± 6.5* 79.5 ± 13.9# 83.4 ± 18.5*
Lymphocytes 5.6 ± 5.4 13.3 ± 14.3# 3.9 ± 4.4* 2.6 ± 3.0* 2.9 ± 2.2*
Eosinophiles 1.1 ± 2.2 0.8 ± 2.6 0 ± 0 0.5 ± 1.6 0.7 ± 1.5
Neutophiles 6.2 ± 7.8 13.4 ± 13.5 5.1 ± 5.0 14.5 ± 13.7 11.7 ± 18.4
Bronchial epithelial cells 1.7 ± 1.2 3.2 ± 3.8 1.2 ± 1.5 3.0 ± 4.4 1.3 ± 1.6
The numer of cases in groups 15 17 12 21 21
Stage IA — active sarcoidosis in stage I; stage IB — inactive sarcoidosis in stage I; stage II/III A — active sarcoidosis in stage II and III; stage II/IIIB — inactive sarcoidosis 
in stage II and III; group K — control group 
*values significantly different versus stage II/III A (p < 0.05) 
#values significantly different versus stage IB (p < 0.05)
400
410
420
430
440
450
460
470
480
490
Pkt. 0 Pkt. 1 Pkt. 2 Pkt. 3 Pkt. 4
Consecutive cycles of sputum induction
Control group Sarcoidosis
P
EF
L/
m
in
Figure 1. PEF values before and after each inhalation cycle in heal-
thy group and patients with sarcoidosis 
interrupted after the fourth inhalation cycle due 
to a feeling of dyspnoea; the PEF value decreased 
by 10% from baseline at that time (from 300 l/min 
to 270 l/min). Dyspnoea regressed five minutes 
after administration of an additional salbutamol 
dose, and the PEF value returned to baseline after 
15 minutes. All patients reported a salty taste in 
their mouth during the procedure, but this was the 
reason for early test interruption only in a single 
subject (induction interrupted after two minutes of 
the fourth cycle). Three persons reported nausea 
during induction but only a single female patient 
interrupted the procedure because of that, after 
the second nebulisation course.
Discussion
The procedure of sputum induction is 
a promising technique, which can contribute 
information concerning cellular constituents but 
also chemical composition of the bronchial fluid 
after the fourth induction cycle. In another female 
patient, aged 52, presenting stage III/IV sarcoido-
sis and spirometric signs of obturation (FEV1 of 
76.2% of the expected value), the procedure was 
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liquid phase. Changes in sputum cell composition 
may reflect bronchial inflammation in patients 
with asthma and chronic obstructive pulmonary 
disease [4, 28, 32], and the obtained results are 
comparable to data from analysis of BAL samples 
and biopsies of bronchial mucosa [24, 26, 31, 33]. 
Sputum induction in diagnostics of tract diseases 
is proposed as an alternative to more invasive 
procedures [7, 8, 16]. 
Bronchoalveolar lavage (BAL) is a widely 
accepted diagnostic method in interstitial lung 
diseases, including sarcoidosis [9, 12]. Cytological 
data from samples obtained through this procedure 
reflect the composition of inflammatory infiltrate 
in lung parenchyma [13, 14]. Induced sputum is 
obtained from more central parts of the bronchial 
tree. However, during a 20-minute-long procedure, 
cell material can be obtained also from distal parts 
of the respiratory tract and lung alveoli [30]. Mo-
reover, in patients with sarcoidosis, lymphocytic 
infiltration was found not only in lung interstitium 
but also in bronchial epithelium [34, 35]. These 
findings suggest that not only BAL but also indu-
ced sputum can have significantly different cell 
composition in patients with sarcoidosis and in 
healthy subjects.
Many authors have compared cell compo-
sition of induced sputum from patients with sar-
coidosis and from subjects with other interstitial 
lung diseases, suggesting the applicability of this 
method for differential diagnostics [5, 17, 36, 37]. 
A higher percentage of lymphocytes was found in 
IS from patients with sarcoidosis as compared to 
healthy subjects [38–40]. No such difference was 
observed in the presented study when all patients 
with sarcoidosis were analysed as one population 
(group A+B). The percentage of lymphocytes was 
clearly higher in patients with sarcoidosis than 
in the control group, but the difference was not 
statistically significant. This discrepancy can be 
explained by the composition of the patient gro-
up. In the above-cited studies, included patients 
had newly diagnosed, active sarcoidosis, in which 
numerous lymphocytes can be found at the sites 
of inflammation [10, 41]. In the presented study, 
patients with ongoing as well as subjects with cli-
nically inactive sarcoidosis were included, which 
resulted in less prominent differences in lympho-
cyte count as compared to healthy subjects. When 
patients with non-active sarcoidosis were excluded 
to a separate group in analysis, no differences in 
lymphocyte percentage were observed in IS as 
compared to healthy controls. These findings can 
suggest that analysis of cell composition in IS may 
not yield diagnostically important information in 
the entire population of patients with sarcoidosis 
or in persons with non-active disease.
When patients with active sarcoidosis were 
analysed as a separate subgroup, a significantly 
higher percentage of lymphocytes and lower ma-
crophage counts were found in IS in these subjects 
as compared to healthy controls, similarly to re-
ports from other authors. The observed lymphocyte 
percentage in IS in sarcoidosis is similar to values 
reported by other authors, who also analysed the 
entire amount of the obtained expectorate [37, 38]. 
There were no significant differences in eosinophil 
or neutrophil percentages between the studied gro-
ups in the presented study, which is in accordance 
with data from literature [38–40]. D’Ippolito also 
assessed the amount of bronchial epithelial cells 
in IS, and found a higher bronchial epithelial cell 
content in patients with sarcoidosis as compared 
to healthy persons [38]. In the presented study, 
the percentage of bronchial epithelial cells was 
also higher in subjects with sarcoidosis, but the 
difference was not significant, although nearly 
significant when comparing healthy persons to 
patients with active sarcoidosis. Bronchial epithe-
lial cell content was not analysed in many studies 
analysing samples from patients with sarcoidosis 
and healthy persons [15, 36, 39, 40].
In the presented study, the cell composition 
of IS was evaluated in various stages of sarcoido-
sis. Particularly high lymphocyte percentage was 
observed in samples from stage II and III active 
sarcoidosis, clearly exceeding values found in 
patients with non-active disease or in healthy sub-
jects. The difference in lymphocyte percentage was 
not significant between stage I active sarcoidosis 
and other groups. Many of these patients had re-
latively few lymphocytes in IS; however, in three 
subjects lymphocyte percentage exceeded 10%. 
The highest value was observed in a male patient 
in whom conventional chest X-ray yielded diagno-
sis of stage I sarcoidosis but HRCT scans revealed 
ground glass attenuation, pointing to an active 
interstitial disease. Higher lymphocyte percentage 
in IS from patients with stage II and III sarcoidosis 
may possibly be explained by the admixture of 
cells originating from the most peripherally loca-
ted parts of the respiratory system or by a higher 
intensity of inflammation in the central parts of the 
bronchial tree in patients with interstitial changes. 
The above-mentioned studies investigated IS from 
patients with stage II sarcoidosis only [37] or from 
patients with different stages of disease analysed 
as one group [5, 17, 36, 38, 39].
In the presented study, a relatively low per-
centage of neutrophils was observed in IS from 
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patients in all of the studied subgroups. Many 
authors, investigating IS from patients with sar-
coidosis and other diseases have reported higher 
neutrophil percentages, up to 40% [17, 39, 42]. 
This discrepancy may be explained by metho-
dological differences between respective studies 
[30, 43, 44]. Many authors who applied a nebuli-
sation procedure of similar length to the presented 
study, and included thorough and multiple cycles of 
oral cavity cleaning, observed even lower neutrophil 
counts than in the presented material [4, 38, 40, 44].
Altered osmolarity inside the respiratory 
tract after inhalation of hypertonic saline solu-
tion causes transient hyperreactivity of the bron-
chial tree and may induce bronchospasm during 
the procedure of sputum induction [25, 45, 46]. 
In order to avoid this phenomenon, inhalation of 
a bronchodilating agent precedes inhalation of 
saline solution under the procedure of sputum 
induction. The most commonly used agent is 
salbutamol [8, 27], which was demonstrated to 
more efficiently prevent bronchospasm during 
sputum induction [47] and had no effect on 
differential cell count in the obtained samples 
[48, 49]. Following such a procedure, sputum 
induction is safe and well tolerated by healthy 
subjects and by patients with chronic obstructive 
pulmonary disease, asthma, or interstitial lung 
diseases [50–53].
The sputum induction procedure was well 
tolerated in the presented study. The observed PEF 
decrease during induction was statistically signi-
ficant, but the greatest registered mean decrease 
in this parameter was 20.43 l/min (4.44% of the 
expected value), and occurred after the third ne-
bulisation cycle. The procedure was interrupted 
due to dyspnoea or PEF decrease of > 20% from 
baseline in two patients, and symptoms quickly 
disappeared after administration of another dose 
of salbutamol. 
Conclusions
Sputum induction is a safe diagnostic method, 
well tolerated by patients with sarcoidosis. The 
evaluation of IS differential cell counts does not 
seem to be of much importance for disease diagno-
stics. However, observation of increased lympho-
cyte percentages in sputum samples can be of use 
in the assessment of disease activity, especially in 
patients with interstitial lung changes.
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